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PROSPECTIVE STUDY OF OUTCOMES IN SPORADIC VERSUS 
HEREDITARY BREAST CANCER
DM Eccles, PD Simmonds, SM Gerty
University of Southamtpon, Southampton, United Kingdom
This prospective cohort study has been recruiting women aged  40 years
at breast cancer diagnosis since June 2001. MREC was amended to include
women up to 50 years if they are known BRCA1 or BRCA2 gene carriers
and diagnosed in the period since December 2001. Initial slow progress has
been greatly facilitated since adoption into the National Cancer Research
Network and a rapid increase in the rate of recruitment has occurred in the
last year with over 50 hospitals now actively recruiting and the majority of 
cancer research networks active. Recruitment at the end of January 2004
stands at 432 with a steep rise in month on month recruitment in the last year 
with current recruitment at 50-60 patients per month. We have examined 
some of the available data on the characteristics of this unusual cohort.
All patients have been diagnosed since December 2000. The average age
at diagnosis is 35 (range 23-46). The heterozygote (HZ) risk (chance of 
carrying a high risk breast cancer susceptibility gene) for participants is
derived from the reported family history and reveals that 11% have a HZ risk 
of  79% with a high likelihood of being BRCA1 or BRCA2 gene carriers
(some are already known gene carriers). 65% have a HZ risk  21% and 
are most likely not to be due to major predisposition genes. The remaining
24% have an intermediate genetic risk amongst whom the proportion of 
BRCA1 and 2 gene carriers will be intermediate and in many cases disease
will be due to polygenic inﬂ  uences.  The vast majority of patients presented 
symptomatically. Tumour stage is similar in all risk groups but reported 
tumour grade for the high HZ risk patients had a higher proportion of high
grade oestrogen receptor negative tumours than the other groups. Current
studies planned using this cohort and executable during the accrual phase
include a series of clinical comparisons between sporadic and hereditary
groups and association studies to examine candidate gene polymorphisms
for low penetrance  susceptibility. The projected date for completion of the
accrual of 2000 cases is June 2006, follow up will continue for a minimum
of 5 years.
P2
TRENDS AND REPRODUCTIVE RISK FACTORS IN FEMALE
BREAST CANCER INCIDENCE IN GREAT BRITAIN
P.S. Carroll
Pension and Population Research Institute, London, United Kingdom
National trends in incidence according to age of women are examined
in relation to contemporary data on known risk factors for both the main
jurisdictions in Great Britain for successive female birth cohorts born in
the years since 1926.  Forecast numbers of new malignant breast cancers
for England & Wales and for Scotland  for years up to 2026 are produced
using a linear probability model ﬁ  tted to national data on birth cohorts
of the female population.  The response variable is cumulated cohort
breast cancer incidence within the ages 50 to 54.  The two explanatory
variables, used in the model as the best predictors among reproductive
risk  factors, were cumulated cohort rates of  fertility and  induced
abortion.  Allowance is also made for the additionally carcinogenic
effect of nulliparous abortions. The analysis and modelling for Great
Britain is compared with Sweden and the Czech Republic.
This modelling is also applicable to mortality trends as reported recently
in Health Statistics Quarterly by ONS. [1] “In women, the inverse social
class gradient in breast cancer increased…”  The gradient across social
class is explicable in terms of the same reproductive risk factors and a
further increase in the inverse gradient can be anticipated.
The research updates research previous published [2] by the International
Congress of Actuaries in Mexico in 2002, where the modelling focused
on the incidence of breast cancer within the ages 45 to 49.  
References: 
1. Trends in social class differences in mortality by cause, 1986 to 2000.
Chris White, Folkert van Galen, Yuan Huang Chow. Health Statistics
Quarterly No 20. Winter 2003. ONS.
2. Pregnancy Related Risk Factors in Female Breast Cancer Incidence.
Patrick Carroll.  International Congress of Actuaries, Cancun, Mexico.
Transactions (2002) 4:331-75
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USE OF MAGNETIC RESONANCE IMAGING TO PLAN BREAST
CONSERVING SURGERY FOLLOWING NEOADJUVANT
CHEMOTHERAPY FOR BREAST CANCER
M Bhattacharyya, S Vinnicombe, D Ryan, R Al-Mufti, R Carpenter,
C Gallagher 
St Bartholomew’s Hospital, London, United Kingdom
Background: Selection of patients (pts) for breast conserving surgery
(BCS) following neoadjuvant chemotherapy (NAC) is dependant upon
accurate assessment of the extent of residual disease within the breast
Up to 60% patients  fail primary surgery and require re-excision or 
mastectomy.
Methods: Pts seen over a 3-year period, with histologically conﬁ  rmed 
invasive breast cancer on core biopsy, stage cT2 –  T  3, eligible for 
NAC and potentially suitable for BCS were included. Pre and post 
2 3
NAC mammography  (MM),  breast ultrasound  (U/S), and MRI were
independently reported and compared w ith c linical and pathological
assessment.  
Results: 32 pts median age 42 years were treated; 69% pre-menopausal;
stage I 6%, II 62%, III 31%. Median tumour size pre-NAC was 4.75cm.
All received 6 cycles of chemotherapy.  Clinical response: CR 12.5%,
PR 81.3% SD 6.2%. MM in this young population was uninformative in
62.5%.  U/S and MRI correlation with pathological response was r= 0.65
and r=0.71 respectively.  In 4 pts, MRI tumour size was > 1cm larger than
pathological size due to associated DCIS in 3 and post treatment hyaline
ﬁ  brosis in 1 patient.  In 2 pts, MRI size was > 1cm smaller because of 
delayed surgery.  MRI but not U/S was able to differentiate between
residual  invasive tumour and DCIS or ﬁ  brosis  from the  gadolinium
enhancement curves.   
Following NAC 25 (72%) were suitable for BCS (unsuitable- proximity
to nipple 5, multifocal 1, skin tethered 1) of whom 20 proceeded (3 chose
mastectomy, 2 radiotherapy only).  17 (85%) pts had successful initial
surgery, 3 (15%)had positive margins requiring re-operation because of 
difﬁ  culty locating very small residual masses.
Conclusion: MRI aided the selection of pts for BCS after NAC due to the
high correlation with pathological ﬁ  ndings.  72% pts achieved BCS, 85%
of them with single operation.
P4
DENDRITIC CELLS WITH IMMATURE PHENOTYPE AND 
DEFECTIVE FUNCTION IN SOLID TUMOURS FROM PATIENTS
WITH BREAST CARCINOMA
S Islam 1, M Burke 1, SC Knight 2
1 Antigen Presentation Research Group, Imperial College London, 
London, United Kingdom, 2 Northwick Park Hospital, London, United 
Kingdom
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NAVELBINE (NV) AND TRASTUZUMAB (TR) IN COMBINATION
FOR ADVANCED BREAST CANCER: A RETROSPECTIVE 
SINGLE INSTITUTION ANALYSIS
T Benepal, G Attard, SRD Johnston, IE Smith
Royal Marsden Hospital, London, United Kingdom
Tr in combination with Taxol is an accepted combination for use in r
advanced breast cancer. Non-randomised data also suggest that Nv
is active in combination with Tr. We performed a retrospective single
institution analysis of 19 women with advanced breast cancer treated 
with t he combination over a 20 month period  from May 2002 to
December 2003. Their median age was 55 yrs (range: 25-74). All the
patients treated had evidence of disease progression prior to therapy.
All tumours were conﬁ   rmed, prior to treatment, to be Her2 3+ by
immunohistochemistry. Thirty seven percent (7/19) were ER negative.
Sixteen percent (3/19) were grade 1 ER positive, 26% (5/19) grade 2
ER positive, and 21% (4/19) grade 3 ER positive on staining.  A median
of 6 cycles of chemotherapy were given (range 1-8). All patients were
scheduled to receive Nv at 25 mg m-2 days 1 and 8 of a 21 day cycle.
Tr was given weekly at 2 mg kg r
-1 in 15 patients and three weekly at 6
mg kg-1 in the other 4. One patient received the combination 1st line;
seven 2nd line, nine 3 d rd line and one 4 d th line. The regimen was well
tolerated: neutropaenia was the only grade 3 or 4 toxicity and occurred 
in 5 patients. Lethargy was the commonest non-haematological toxicity.
Forty seven percent (9/19) of patients responded to treatment, including
6 who were ER negative. A further 21% (4/19) had stable disease, and 
32% (6/19) progressed on treatment. Of the 10 patients with stable
or progressive disease only 1 was ER negative. We conclude that this
combination is well tolerated and this small series suggests that it may
be more effective in patients with ER negative tumours. This issue
should be further assessed in other series.
P6
AGE INFLUENCES THE BIOLOGY OF PRIMARY BREAST
CANCER
JR Buckley, GA Thomas, K Malinovszky, C Jones, RCF Leonard 
Cancer Institute Swansea University, Swansea, United Kingdom
Factors that have been found to relate to the prognosis of breast cancer
include tumour size, node status and oestrogen receptor (ER) status.
With changing demographics and a consequent interest in managing
disease in the aging cancer population, there is a need to ascertain
biological differences between cancers of the young and old.  These
ﬁ  ndings may have implications for targeting treatment.  The dividing
line between pre- and post-menopausal cases is a signiﬁ  cant one when
deciding about treatment policy.  Eppenberger-Castori et al  (2002)
studied a large group of cases comparing different age-groups in terms
of biological markers and found that there was an association between
some biological markers and age.  
We determined to do similarly, but selected extremes of the age
spectrum by studying local cases of the disease.  We compared a young
pre-menopausal group (aged under 43) with two older post-menopausal
groups (aged 70 to 72 and over 84 respectively, subsequently, because
of their similar ﬁ  ndings, combining them to form one elderly post-
menopausal group).
We  found statistically signiﬁ  cant  positive correlations  between
advancing age and ER status (2 = 13.8579, P < 0.001) and node
positivity (2 = 5.6559, 0.01 < P < 0.025).  There were positive trends
between advancing age and increasing tumour size and Nottingham
Prognostic Index (NPI).  Statistically signiﬁ  cant negative correlations
were found between advancing age and grade (2 = 15.0567, P <
0.001). 
In conclusion, despite an increased ER positivity, older patients have
a poorer prognosis for cause-speciﬁ  c survival based on these features,
which is reﬂ  ected by NPI score.  Therefore, there are marked differences
in tumour biology between young and old.
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LOW 25HYDROXYVITAMIN D3 LEVELS AND BREAST CANCER 
RISK IN A UK CAUCASIAN POPULATION
LC Lowe 1, M Guy 1, K Townsend 2, MJ Campbell 2, M Hewison 2,
JL Mansi 1, KW Colston 1
1 St. George’s Hospital Medical School, London, United Kingdom,
2 The University of Birmingham, Birmingham, United Kingdom
The active  form of v itamin  D3, 1,25dihydroxyvitaminD3  (1,25-D3)  is
known to have anti-carcinogenic properties in various cancer cell types,
including breast. 1,25-D3 is produced from 25hydroxyvitaminD3 (25-D3)
by the enzyme 1  hydroxylase (1 OHase, encoded by the Cyp27b gene).
While 1 OHase was thought to be exclusively a renal enzyme, recent
evidence has shown it is active in other tissues, suggesting local 1,25-D3
production at sites other than the kidney. Our aim was to determine if 
breast tissue expresses 1 OHase and whether breast cancer patients have
lower levels of circulating 25-D3 than controls. Paired normal and tumour 
breast tissue samples from 41 Caucasian patients (taken with full ethical
approval) were analysed for Cyp27b mRNA expression using real time
RT-PCR. Normal breast exhibited strong expression of Cyp27b and this
expression was increased in oestrogen receptor (ER) positive tumours
(mean = 23 fold increase, P<0.0001, n=29) and ER negative tumours
(mean = 57 fold increase, P<0.0001, n=12). This indicates that 1,25-D3
may be generated locally in the breast and that circulating 25-D3 levels
may inﬂ  uence its production. Circulating 25-D3 levels were measured by
ELISA in 179 Caucasian breast cancer patients recruited with full ethical
approval and 179 Caucasian control volunteers, matched for time of year,
age and menopausal status. Breast cancer patients had signiﬁ  cantly lower 
25-D3 levels than controls (80.13nM +/- 43.44 vs. 97.6nM +/- 40.87,
p=0.0001). Furthermore, when all values were separated into quartiles,
it was found that women in the lowest quartile had an odds ratio (OR) of 
5.19 (95% conﬁ  dence interval 2.23-12.08, p=0.001) for breast cancer risk 
compared to women in the highest quartile. In conclusion we hypothesise
that low circulating levels of 25-D3 diminishes the ability of the breast
to  locally produce 1,25-D3 and so may contribute to breast cancer 
development. 25-D3 measurements may serve as a marker for women at
higher risk of breast cancer.
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THE 5A/6A POLYMORPHISM OF THE STROMELYSIN I GENE
PROMOTOR AND BREAST CANCER 
P Krippl, U Langsenlehner, T Eder, H Samonigg 
Division of Oncology, Medical University Graz, Graz, Austria
Purpose: The matrix metalloproteinase 3 (MMP3), also known as
stromelysin-I, is a key-player for carcinogenesis and tumor growth. A
5A/6A promoter polymorphism is associated with differences in MMP3
activity and has been linked to cancer susceptibility in some studies. In
the present study we evaluated the role of this polymorphism for breast
cancer risk.
Patients and Methods: A case-control study was performed including
500 patients with histologically conﬁ   rmed breast cancer and 500
female, age-matched, healthy control subjects from population-based
screening studies. The MMP3 5A/6A polymorphism was determined by
a 5’-nuclease (TaqMan) assay.
Results: Prevalences of 5A/5A, 5A/6A and 6A/6A genotypes were
similar among patients (20.6%, 51.8%, 27.6%) and controls (23.3%,
47.3%, 29.4%, p = 0.34). The odds ratio of carriers of a MMP3 5A
allele for breast cancer was 1.09 (95% conﬁ  dence interval 0.83 - 1.44).
Patients with the 5A/5A genotype had a higher proportion of lymph-
node metastases than those with a 5A/6A or 6A/6A genotype (P =
0.010).
Conclusion: The MMP3 5A/6A promoter polymorphism does not
appear to inﬂ  uence breast cancer susceptibility, but may be linked to a
higher risk for metastasizing among breast cancer patients.
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THE SULT1A1 213H VARIANT IS ASSOCIATED WITH THE 
PRESENCE OF LYMPH NODE METASTASES IN BREAST
CANCER PATIENTS
U Langsenlehner, P Krippl, T Eder, H Samonigg 
Division of Oncology; Medical University Graz, Graz, Austria
Background: Sulfotransferase 1A1 (SULT1A1) is involved in the
bioactivation and detoxiﬁ  cation of a variety of xenobiotic compounds,
especially in the inactivation of estrogens. A common arginine (R) to
histidine (H) variation at amino acid position 213 inﬂ  uences SULT1A1
activity and has been suggested as a risk factor for a variety of cancers.
Patients and methods: To investigate the role of this polymorphism for 
breast cancer risk, SULT1A1 genotype was determined in 500 women
with c linically veriﬁ  ed  breast cancer and 500 female age-matched 
healthy control subjects. Genotyping was done by a 5’-nuclease assay
(TaqMan). Primer and probe sets were designed and manufactured 
using Applied Biosystems ‘Assay-by-Design’ custom service. P-values
were calculated by χ2 test using SPSS 10.0. All tests were two-sided,
threshold for signiﬁ  cance was P < 0.05.
Results: Frequencies of heterozygous  (controls: 42.5%; patients:
50.2%) or homozygous (controls: 12.6%; patients: 9.4%) carriers of 
the 213H variant were not signiﬁ  cantly different between groups. The
odds ratio of the SULT1A1 R213H variant was 1.20 (95% conﬁ  dence
interval 0.94 – 1.55) in a dominant model (RH+HH versus RR) and 
0.72 (95% conﬁ  dence interval 0.48 – 1.08) in a recessive model (HH
versus RH+RR), respectively.The SULT1A1 genotype was furthermore
not associated with tumor size, histological  grading, estrogen or 
progesterone receptor status and age at diagnosis. The SULT1A1 213H
variant was associated with the presence of lymph node metastases
(p = 0.002).
Conclusion: We conclude that the SULT1A1 R213H polymorphism is
not a general risk factor for breast cancer, but may be involved in lymph
node metastazing in breast cancer patients. Further prospective studies
should be performed to analyze this potential role of the SULTA1
polymorphism for lymph node metastasis development.
P10
THE 677C>T POLYMORPHISM OF METHYLENETETRAHYDRO
FOLATE REDUCTASE GENE AND SUSCEPTIBILITY TO BREAST
CANCER
U Langsenlehner, P Krippl, H Samonigg 
Division of Oncology, Medical University Graz, Graz, Austria
Introduction: Methylenetetrahydrofolate reductase (MTHFR) is
involved in folate metabolism and plays a role in DNA biosynthesis,
methylation, and repair in actively dividing cells. A common 677C>T
polymorphism in the gene for MTHFR, leading to a thermolabile
enzyme with  decreased activity,  has  been associated w ith reduced
plasma folate levels and elevated homocysteine levels and could be a
risk factor for breast cancer.
Patients and Methods: In the present case-control study, MTHFR
genotype was determined in 500 women with clinically veriﬁ  ed breast
cancer and 500 female age-matched healthy control subjects. A fragment
containing the polymorphic site was ampliﬁ  ed by polymerase chain
reaction. Statistic analysis was done using SPSS 11.0 for Windows.
Numeric values were analyzed by Student’s t-test, proportions of groups
were compared by χ2 test. 
Results: The homozygous TT genotype was found in 13.0% patients and
13.1% controls (p = n.s.). The odds ratio of TT homozygotes for breast
cancer was 0.99 (95% conﬁ  dence interval 0.68 – 1.43). The MTHFR
genotype was furthermore not associated with tumor size, histological
grading, estrogen or progesterone receptor status and age at diagnosis.
In a subgroup of 116 premenopausal patients, no increased frequency of
the homozygous 677T genotype was found (13.8%).
Conclusion: Therefore, we conclude that the MTHFR 677C>T
polymorphism is not associated with individual susceptibility to breast
cancer.
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THE EFFECTS OF A NOVEL CDK INHIBITOR ON TAMOXIFEN
SENSITIVE AND RESISTANT BREAST CANCER CELL LINES
N Johnson, N Curtin
Northern Institute for Cancer Research, University of Newcastle Upon
Tyne, Newcastle, United Kingdom
Antiestrogens such as tamoxifen have been the standard treatment for 
estrogen receptor (ER) positive breast cancers. Tamoxifen antagonises
estrogen – ER interactions resulting in down regulation of ER-mediated 
gene transcription which results in p27 accumulation. p27 inhibits
CDK2/cyclinE/A complexes involved in the G1/S transition. Elevation
of p27 levels by tamoxifen causes cell cycle arrest and inhibition of 
breast cancer cell growth. However, less than half of breast cancers
respond to tamoxifen therapy and antiestrogen resistance usually
develops. Direct inhibition of CDK2 may inhibit the growth of hormone
refractory as well as hormone responsive  breast cancers. The novel
CDK inhibitor NU2058 inhibits the activity of CDK2 (IC50 16.6 ± 2 µM)
and CDK1 (IC50 26 ± 3.5 µM) and was investigated in breast cancers
with different sensitivities to tamoxifen.
The ER status of MCF7 and MCF7/LCC9 cells (a tamoxifen resistant
MCF7 derived cell line) were measured (western blot) to give an
indication of the importance of ER levels in predicting tamoxifen
sensitivity. ER expression was more than twice as high in MCF7 than
MCF7/LCC9 cells. In 6 day  growth inhibition experiments (SRB)
tamoxifen was 4 times as potent in MCF7 than in MCF7/LCC9 cells but
NU2058 was equally effective in both cell lines (see table). 
Cell line            ER (fmoles/mg
cellular protein)
Tamoxifen
GI50 (µM)  
NU2058 GI50
(µM)
MCF7 124 ± 74 2 ± 0.4 27 ± 3
MCF7/LCC9 55 ± 32 8 ± 1.2 34 ± 10
In conclusion, tamoxifen effects on cellular proliferation are more
pronounced  in tamoxifen sensitive MCF7 cells than  in tamoxifen
resistant MCF7/LCC9 cells. In contrast, the effects of NU2058 were
similar in both cell lines.
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IS HIC1 (HYPEMETHYLATED IN CANCER 1) A THERAPEUTIC 
TARGET IN BREAST CANCER?
H McDowell 1, G Nicoll 1, G Thomson 2, NM Kernohan 2,
D Martin 2, AM Thompson 1
1 Department of Surgery and Molecular Oncology, University of 
Dundee, Dundee, United Kingdom, 2 MRC/CRUK Tissue Bank,
University of Dundee, Dundee, United Kingdom
A transcriptional repressor gene, HIC1 (hypermethylated in cancer),
on chromosome 17p may be of clinical importance with therapeutic
potential in sporadic breast cancer.  Preliminary data from our laboratory
demonstrated failure of HIC1 expression in 86% of ﬁ  fty breast cancers
but conversely, HIC1 expression appeared to be associated with good
prognostic features. The aim of this study was to conﬁ  rm these ﬁ  ndings
on a second series of breast cancers and to compare HIC1 expression to
p53 function since p53 may transcriptionally activate HIC1.
Based on 250 breast cancer samples, HIC expression was successfully
determined in 153 cancers using polymerase chain reaction (PCR)
based techniques and identiﬁ  ed at normal levels or overexpressed  in
the cancer from 14/153 (9%) patients. In these 14 patients, the genomic
HIC1 DNA failed to show mutation using Wave but p53 mutation was
identiﬁ  ed with the yeast functional assay and conﬁ  rmed by sequencing
in 4 tumours. The same series of 250 cancers was examined for p53
protein expression using immunohistochemistry with antibodies DO1,
DO7, Ser15 and FP3. 
Comparison of HIC1 gene expression as a continuous or dichotomous
variable with clinical and pathological parameters demonstrated no
statistically signiﬁ   cant associations. There was also no association
between HIC1 expression and p53 immunohistochemistry.
This study conﬁ  rmed suppression of HIC1 in the majority (86%) of
breast cancers. However, where HIC1 expression remained, neither
HIC1 nor p53 were commonly mutated and we thus conclude that HIC1
may be a bystander in breast cancer rather than a suitable target for novel
therapeutic intervention.
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BREAST CANCER AND HORMONE THERAPY IN 
POSTMENOPAUSAL WOMEN
LE Turner 1, NJ Bundred 2
1 The University of Manchester, Manchester, United Kingdom, 
2 Academic Surgery, South Manchester University Hospital, 
Manchester, United Kingdom
Introduction: Menopausal symptoms such as hot ﬂ  ushes, night sweats
and osteoporosis lead to considerable morbidity in the Western World.
Women with breast cancer often develop an early menopause due to
treatment effects such as chemotherapy. Osteoporosis causes fractures
in around 3-5% of breast cancer patients on adjuvant endocrine therapy
(particularly after aromatase inhibitor therapy).  Hormone replacement
therapy (HRT) is effective in relieving menopausal symptoms but its use is
generally discouraged in women with breast cancer. 
Aims: To determine the incidence of menopausal symptoms and to
identify w hat factors predicted HRT use in women with breast cancer 
compared to a control group. The frequency of osteoporosis or osteopaenia
was determined in a sub-group of 70 women with early breast cancer who
had recent Lunar Hologic Dual Energy X-ray Absorptiometry (DEXA).
Results: Incidence and severity of menopausal symptoms were greater 
in 146 women with breast cancer, particularly those on adjuvant therapy
or after chemotherapy compared to 133 controls (p<0.05).  Psychosocial
problems such as depression, state anxiety and loss of sexual interest were
signiﬁ  cantly dependent of group (p<0.05). Factors associated with HRT
use were the need for effective treatment of symptoms (positive correlation,
p=0.01) and women with breast cancer (negative association, p=0.03). 4%
of the sub-group were osteoporotic and 33% were osteopaenic. Of women
who were 60 years or older, 38% were osteopaenic, of those who were
smokers (previous or current), 50% were osteopaenic compared to 25% of 
non-smokers (p>0.05).
Conclusion: For women with breast cancer the menopause has a huge
impact on quality of life. Women in whom adjuvant aromatase inhibitor 
is proposed require baseline bone mineral density scanning prior to its
commencement.  Screening menopausal s ymptoms  is  imperative to
address the needs of women with breast cancer. 
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CENTRAL NERVOUS SYSTEM METASTASES IN WOMEN WITH
METASTATIC BREAST CANCER
M Hawkins, S Lalondrelle, AJ Neal
United Kingdom, St.Luke’s Cancer Centre, Guildford
Introduction Trastuzumab (T) is the drug of choice in women with
metastatic breast cancer overexpressing HER-2. T does not cross the
blood-brain barrier.
Methods This is a retrospective study looking at a cohort of patients
with metastatic breast cancer (MBC) in St. Luke’s Cancer Centre
Guildford over the period March1999-March 2003. 68 patients with
HER-2 3+ MBC who have received T alone or in combination have been
identiﬁ  ed, but only 60 had adequate details. None of the patients had
central nervous system disease (CNS) prior to starting T. The median
follow-up of the cohort was 24 weeks from commencing T.
Results 16 patients (26.6%) developed brain metastases (BM) while on
T. Median time follow up on T was 44 weeks in patients who developed
BM versus 20 weeks in patients who did not. 13 out of 16 patients who
developed BM had partial response or stable systemic disease when BM
was diagnosed. Following the diagnosis of BM, all patients received
whole brain radiotherapy. Median survival following diagnosis of BM
was 6.5 months. 11 out of 16 patients died of progressive brain disease
following the diagnosis of BM.  The initial disease free interval from
diagnosis of cancer was longer in patients who developed BM: 32.5
months versus 21 months. There were 16 deaths in the non-BM patients
due to liver failure and the median duration of treatment in this group
was only 14 weeks.
Conclusion T is effective in treatment of HER2 3+ patients. There is a
group of patients who respond well and despite having stable visceral
and bone disease, develop BM ultimately causing mortality. Interestingly
another group of patients  has  been  identiﬁ  ed w ho  has  different
characteristics: shorter disease free interval from the diagnosis of breast
cancer, and in which once metastatic disease developed response to T is
brief and death occurs due to liver or multiorgan failure.
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TIME AND CHEMOTHERAPY TREATMENTS TRENDS IN
THE ELDERLY (AGE>70) WITH LUNG CANCER IN A SINGLE UK 
CANCER  CENTRE
Yau Thomas, Asley Sue, Norton Alison, Athena Matakiou, Popat 
Sanjoy, David Watkins, Tim Eisen, Simth IE, O’Brien Mary
Royal Marsden Hospital, London, United Kingdom
Background:There are few data on the outcome in elderly patients(>70) with 
lung cancer over the past 20 years. Equally, there is little know about long term 
outcomes when treated with chemotherapy.  This study focuses on elderly lung
cancer patients(age>70) in a single UK cancer centre treated over  the past 20
years. 
Methods: We retrospectively reviewed 90 patients who received treatment 
for  lung cancer(NSCLC,SCLC and mesothelioma)at the Royal Marsden 
Hospital(RMH) between 1982 and 2003. Patient characteristics, type of 
tumours, stage, performance status(PS), year of presentation, treatment and 
cause of death were analyzed. Survival analysis was done by Kaplan Meier 
method.Comparion of all cause survival was done between patients presenting
in  1982-1994 and 1995-2003 by the log rank test. Comparison of survival
between different  treatment regimes used the proportional hazards model. 
Results: There has been an improvement in all cause survival(adjusted for 
sex,stage and PS)  in all age groups. Between 1982 and 2003, there were 960
elderly patients:519 aged 70-74, 328 aged 75-79 and 113 aged >80. Of these,
55% of patients had NSCLC, 38 % SCLC and 7% patients had mesothelioma.
Over 85% patients were had performance status 0-2. In the early cohort,  there
were 270 patients and 690 in the most recent cohort. The later group of  has
better survival in all age groups and in particular in patients>80(p<0.001).  The
ﬁ  nding is valid in patients with NSCLC(p=0.008) and SCLC(P=0.0006). As
treatment, 41% patients received a cisplatin combination, 18% a carboplatin 
combination, 4% a non-platinum combination, 17% single agent  and 30 % no
chemotherapy.Carboplatin combinations were signiﬁ  cally better than others
after adjusting for PS , stage and sex(p=0.007).Cisplatin combinations were
found to do marginally better than non-platinum combinations(p=0.06).
Conclusion: This analysis  demonstrated t hat there  has  been a signiﬁ  cant 
improvement  in survival  for elderly patients with  lung cancer in past 20
years after adjustment for stage and PS.Carboplatin combinations seems to
have a greater impact on survival than other combinations or single agent 
treatment.
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A RANDOMISED TRIAL OF EARLY VERSUS DELAYED
CHEMOTHERAPY IN SYMPTOMATICALLY STABLE PATIENTS 
WITH MALIGNANT MESOTHELIOMA
D Watkins 1, M O’Brien 1, S Ashley 1, A Norton 1, C Ryan 2,
A Saini 2, M James 1, K Priest 1, T Eisen 1, I Smith 1
1 United Kingdom, Royal Marsden Hospital, Sutton, 2 United 
Kingdom, Kent Oncology Centre, Maidstone
Background: Prior  phase II trials  have  demonstrated t he therapeutic
activity of cytotoxic chemotherapy in mesothelioma. Currently there is little
randomised data assessing the role of chemotherapy vs best supportive care
(BSC). In the management of patients (pts) with stable symptoms, a policy
of observation may be adopted over initial use of chemotherapy. In this
prospective randomised trial we assess the use of early vs delayed cytotoxic
therapy. The study opened  in 1998, and c losed  in view of a competing
national study (MSO1) in 2003.
Methods: Eligible pts were; Performance status (PS) 2,  life expectancy >3
months and had stable symptoms for at least 4 weeks prior to randomisation.
Pts were randomised to receive immediate chemotherapy or initial BSC with
the addition of chemotherapy at time of symptomatic progression. All pts
received the same platinum based chemotherapy regimen; MVP / MVCarbo
(Mitomycin C 8mg/m2 cycles 1,2,4 & 6, Vinblastine 6mg/m2, max 10mg,
and Cisplatin 50mg/m2 (or Carboplatin AUC 5) every 3 weeks for up to 4-6
cycles. 
Results: A total of 41 pts were recruited. Data are available on 39 pts,
19 of which were randomised to the early treatment (ET) group and 20
to the delayed treatment (DT) group. The median age for the ET and DT
groups were 58 years (range 50-78) and 67 years (range 48-75) respectively
(p=0.07). PS was 0 or 1 in 12 of the ET group and 14 in the DT group. All 19
pts in the early group received chemotherapy vs 15 pts in the delayed group.
A total of 65 cycles of chemotherapy were delivered in the ET group and 40
cycles in the DT group. Median time to symptomatic progression was 25
weeks in the ET group compared to 11 weeks for the DT group (p=0.04).
Median survival was 12 month for the early group compared to 10 months
for the late group (p=0.01).
Conclusion: In this patient group, presenting with initial stable symptoms,
the early use of chemotherapy provided an extended period of symptom
control, and in this small trial, a survival advantage.
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FAMILIAL LUNG CANCER RISKS: RESULTS FROM THE
GELCAPS STUDY
A Matakidou 1, T Eisen 1, M O’Brien 2, H Bridle 1, R Mutch 1,
R S Houlston 1
1 United Kingdom, Sections of Cancer Genetics and medicine, Institute 
of Cancer Research, Sutton, 2 United Kingdom, Lung Unit, Royal
Marsden Hospital, Sutton
Lung cancer is the leading cause of cancer death in the UK. Cigarette
smoking has long been established as the predominant risk factor
for lung cancer with an estimated 90% of cases being attributed to
tobacco exposure. Lung cancer was ﬁ  rst noted to aggregate in families
in the 1960s. Familial aggregation of  lung cancer in the UK was
examined by means of a nationwide, case-control study (GELCAPS)
conducted  between 1999 and 2004. We compared  lung cancer
prevalence in ﬁ  rst-degree relatives of 1004 female patients and 954
female controls. Overall, lung cancer in parents or siblings was
associated with a 1.51-fold (95% conﬁ  dence interval (CI): 1.12-2.04)
increase in lung cancer risk. For the younger participants (below age
61) the risk was 1.95 (95% CI: 1.17-3.24). Analysis by histological
subtype identiﬁ   ed the highest risk in relatives of patients with a
diagnosis of squamous cell lung cancer (OR=1.83, 95% CI: 1.22-2.73)
and the lowest in those with small-cell lung cancer (OR=1.24, 95% CI:
0.78-1.97). Further analysis will be presented in the meeting. Results
conﬁ  rm previous ﬁ  ndings and support the etiologic role of a genetic
predisposition to lung cancer.
P18
CELL CYCLE REGULATORY PROTEINS AS THERAPEUTIC
TARGETS:  A VALIDATED METHOD FOR PHARMACODYNAMIC
EVALUATION OF CLINICAL TRIALS
P Bradbury 1, C Norbury 2, A Olsen 3, M Slade 4, E Cattell 1, D Talbot 1
1 Cancer Research-UK Medical Oncology Unit, Oxford, United 
Kingdom, 2 Sir William Dunn School of Pathology University of 
Oxford, Oxford, United Kingdom, 3 Weatherall Institute of Molecular 
Medicine, Oxford, United Kingdom, 4 OSLER Chest Unit The 
Churchill Hospital, Oxford, United Kingdom
Background:Agents that target cell cycle regulatory proteins are increasingly
being developed to treat cancer. A necessary part of the clinical development
of such agents is proving the mechanism of action at the cellular level. We
report a simple method of validating the mechanism of action of cell cycle
speciﬁ  c drugs using FACS analysis of endobronchial tumour samples. 
Methods: We enrolled informed consenting patients with non-small cell
lung cancer (NSCLC) participating in clinical trials of agents that induce
apoptosis through inhibition of cell cycle proteins. Cell cycle analysis was
performed on bronchial washings  (BW),  bronchial  brushings,  (BB) and
biopsy (BX) aspirates of metastases before and after treatment.  BW, BB and
tumour aspirates were ﬁ  xed in 70% ethanol, stained with propidium iodide
and analysed by ﬂ  ow cytometry. BX were desegregated in PBS/trypsin/
collagenase  before ethanol  ﬁ  xation. Red  ﬂ  uorescence  (DNA)  data were
collected on samples of 10,000 cells. DNA was assessed as apoptotic (<G1
content), diploid (G1 content) or cycling/aneuploid (>G1). BW and BB from
the contralatereal unaffected lung were used as controls.
Results: 23 patients with NSCLC have been studied. BB, BW and BX
but not aspirates generated sufﬁ  cient material for analysis. Tumour cells
exhibited a large variability in aneuploidy compared with normal bronchial
mucosa. Similarly, tumour cells had a greater <G1(apoptotic) fraction than
controls. Treatment caused a large decrease in the >G1 population of tumour
cells and corresponding increase in <G1 fraction. For BX a low proportion
of diploid cells and high levels of presumptively apoptotic cells were seen
prior to treatment: This fraction increased markedly after treatment. These
analyses were more sensitive than radiological response to treatment.
Conclusion: FACS analysis of tissue obtained from BB provides a minimally
invasive but robust, quantitative method for conﬁ  rming the mechanism of
action of novel agents at the cellular level.
P19
A PROSPECTIVE STUDY OF THE INCIDENCE OF
SUB-CLINICAL LAMBERT-EATON MYASTHENIC SYNDROME
(LEMS) IN PATIENTS WITH SMALL CELL LUNG CANCER 
(SCLC)
P Bradbury 1, B Lang 2, A Vincent 2, C Han 1, D Talbot 1
1 Cancer Research-UK Medical Oncology Unit, Oxford, United 
Kingdom, 2 Neurosciences Group Weatherall Institute of Molecular 
Medicine, Oxford, United Kingdom
Background: LEMS is one of the most common paraneoplastic disorders
associated with SCLC. Autoantibodies targeted to the P/Q type voltage gated 
calcium channel (VGCC) are believed to be a cause of LEMS and form the
basis of a diagnostic serological test.  It is not known how many patients
(pts) presenting with SCLC have positive anti-VGCC antibodies (Ab) and 
subclinical LEMS who may then be susceptible to develop clinical LEMS.
We used a sensitive serological test to determine, in a prospective manner,
the incidence of subclinical LEMS in SCLC.
Methods: Consenting Pts with a pathological diagnosis of SCLC completed 
a symptom questionnaire, had clinical examination for signs of LEMS, and 
serum for P/Q anti-VGCC Ab was taken. VGCC Abs were measured by
immunoprecipitation of 
[I125
mmu
125
mmu
]-labelled conotoxin MVIIC bound to VGCCs extracted from healthy
cerebellum. Antibody titres were considered positive if >50pM (Mean +3SD
for healthy controls n=30). Multivariate regression was used to determine the
relationship between clinical symptoms and anti-VGCC titre, Cox analysis
to evaluate survival.
Results: Of the 64 pts (46 male 18 female) tested, 5 (8%) pts had elevation
of t he anti-VGCC antibodies with  levels ranging  from 60-1553pM.
Only one had conﬁ  rmed LEMS on clinical grounds and conﬁ  rmed  by
electrophysiological tests. The other 4 patients did not have clinical evidence
of LEMS. There was no association between anti-VGCC titre and survival
(p=0.08, hazards ratio 0.999) 
Conclusions: This prospective study indicated that increased titre of anti-
VGCC antibodies is common in SCLC.  The presence of antibody positivity
may help to identify patients who are at risk of developing the debilitating
symptoms of LEMS.
P20
CYCLOOXYGENASE-2 PREDICTS SURVIVAL IN MALIGNANT
PLEURAL MESOTHELIOMA
SL O’Kane, A Campbell, MJ Lind, L Cawkwell
PGMI, University of Hull, Hull, United Kingdom
Mesothelioma is a relatively rare, aggressive disease affecting the
mesothelium.  In the past, many cases of mesothelioma may have been
misdiagnosed, mainly as lung cancer.  Nonsteroidal anti-inﬂ  ammatory
drugs (NSAIDs) are known to decrease the incidence of cancer.  One type
of NSAID is the cyclo-oxygenase (Cox) inhibitors.  The Cox enzymes
are involved in the production of prostaglandins from arachidonic acid.
There are three known isoforms of the Cox enzyme: Cox-1, Cox-2, and
the recently identiﬁ  ed Cox-3.  Cox 1 which is inhibited by aspirin for
example, is found in normal tissue and at the site of inﬂ  ammation.  Cox-
2 is inducible and found in neoplastic tissue.  Rofecoxib is an example
of a Cox-2 inhibitor.  Cox-2 has been described as being overexpressed
in a small study of fresh mesothelioma samples. We aimed to assess
Cox-2 on a larger series of archival formalin ﬁ  xed specimens.
Formalin-ﬁ  xed  parafﬁ  n  embedded  resection/biopsy blocks were
obtained from forty  ﬁ  ve  malignant pleural mesothelioma cases (27
epithelial subtype, 8 sarcomatoid subtype and 10 biphasic subtype).
Expression of Cox-2 was detected by immunohistochemical analysis,
carried out on 4µm sections using a monoclonal anti-Cox-2 antibody.
The sections stained with varying intensity and staining was located
in the cytoplasm of the tumour cells.  Positive staining of the reactive
spindle cells in the sections acted as a positive internal control.  Overall
70% of tumour sections were positive.  All sections were independently
scored by two investigators.
Survival was calculated from date of diagnosis to date of death and
analysis was performed with SPSS version 11.0 using a Kaplan Meier
curve.  The results indicate that overexpression of Cox-2 in malignant
pleural mesothelioma is signiﬁ  cantly related to prognosis (p = 0.0171)
and therefore is worthy of further follow up by increasing the number
of cases.
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GEFITINIB (IRESSA) IN ADVANCED NON SMALL CELL LUNG
CANCER (NSCLC): RESPONSE, SURVIVAL AND TOXICITY DATA 
C Thomas, Z kassam, N Shah 
Mount Vernon Cancer Centre, London, United Kingdom
INTRODUCTION: Geﬁ   tinib is an oral selective epidermal growth
factor receptor tyrosine kinase inhibitor, which has shown encouraging
responses in patients with advanced NSCLC. We have retrospectively
analysed the response, survival and toxicity of 33 patients on Geﬁ  tinib
250mg daily with progressive NSCLC, treated in the expanded access
programme from July 2002 to date.
RESULTS:Median age of 60.6 years (38-78), M:F of 1.1:1, performance
status 0/1/2/3: 10/12/9/2.Stage IIIA/IIIB/IV 6/6/21. Tumour response at
2 month using the RECIST criteria showed partial response of 18.8%,
stable disease 31.2% and progressive disease in 50.0%. After a mean
follow up of 4.8 months (0.5- 12.5 months), 21 patients have died with
a mean survival of 4.2 months (0.5- 10 months). Overall symptom
improvement was seen in 36%.Using the Common Toxicity Criteria:
Grade 1 Grade 2 Grade 3 Grade 4
Diarrhoea 6 (18%) 0 1 (3%) 0
Rash 5 (15 %) 3 (9%) 0 0
Oral mucositis 0 1 (3%) 0 0
Periorbital oedema 0 1 (3%) 0 0
Anorexia 1 (3%) 0 0 0
No nausea, pneumonitis, hepatitis, keratitis were reported. There were
no treatment related deaths.
CONCLUSION: Geﬁ  tinib monotherapy  is well tolerated w ith
encouraging early activity and is a reasonable choice of therapy in pre-
treated patients with progressive advanced NSCLC. Detailed toxicity
and survival data will be presented at the meeting.
P22
AUDIT OF GEFITINIB (IRESSA) IN THE MANAGEMENT OF 
NON SMALL CELL LUNG CARCINOMA: A SINGLE INSTITUTES
EXPERIENCE
DA Power, M Beresford, C Lewanski
Charing Cross Hospital, London, United Kingdom
Geﬁ  tinib (IRESSA) is a novel tyrosine kinase inhibitor available on an
expanded access programme as oral monotherapy (250mg per day).
Early studies (IDEAL1&2) had treatment response rates of 11-18% and
40% of patients reported improvement in symptoms.
Aim: to review the use of Geﬁ  tinib at Charing Cross Hospital from July
2002 to date.
Results: 31 patients were treated with Geﬁ  tinib. Male: female ratio 21:
10. Average age at diagnosis 69 years (range 46 – 79). Stage at time
of commencing Geﬁ  tinib: 23% stage IIIB (T4 disease), 77% stage IV .
Prior treatments: radical radiotherapy 22%; surgery 21%; chemotherapy
70%. Geﬁ  tinib was ﬁ  rst line treatment in 30%, second line in 43% and
3rd line in 27%. Symptomatic improvement (exercise tolerance and d
performance score)  in 54%. Radiological partial response in 12%;
progressive disease in 69%. 1 (3%) complete response (female patient,
adenocarcinoma).  Median survival from start of treatment = 3 months
(range 1 - 12). 6 patients died < 6 weeks from starting treatment, without
symptom improvement. Females had improved survival compared to
males - median survival: 26 versus 14 months (p=0.004 log rank). No
effect of histology on survival. Toxicity: Skin rash (acne, palmer-plantar
syndrome) in 67%. Liver enzyme dysfunction in 17%. Diarrhoea;
Grade 1 in 36% patients, grade 2 in 4% (1 patient). No pneumonitits.
3 patients (1%) stopped treatment due to toxicity (2 skin toxicity; 2
hepatic toxicity).
Summary: Geﬁ  tinib is a well tolerated oral treatment. Efﬁ  cacy & toxicity
proﬁ  les appear similar to previous studies. Survival of female patients is
better. Timing & use of Geﬁ  tinib in this poor prognosis disease requires
further investigation. Further survival data will be presented.
P22:1
VALIDATING THE PROGNOSTIC VALUE OF MARKER GENES
DERIVED FROM A NON-SMALL CELL LUNG CANCER 
MICROARRAY STUDY
FH Blackhall, DA Wigle, I Jurisica, M Pintilie, FA Shepherd,
MS Tsao
United Kingdom, Ontario Cancer Institute, Princess Margaret Hospital 
and University of Toronto, Toronto
We previously reported that our cDNA microarray analysis of primary
non-small cell lung carcinoma (NSCLC) could predict for patients at
increased risk of cancer recurrence.  From the result of this analysis, we
selected 11 genes that were potential candidate prognostic marker genes
and used the realtime reverse transcription polymerase chain reaction
(RT-PCR) to investigate their expression in the same set of 38 NSCLC
cases used for the microarray study.  
Cluster analysis of the realtime RT-PCR data for 11 genes separated 
these patients into two groups with signiﬁ  cantly different disease-free
survivals  (log rank test, p<0.017). However, in a validation series
of a further 92 NSCLC cases, cluster analysis failed to conﬁ  rm the
prognostic signiﬁ   cance of the realtime RT-PCR results for these
11  genes.  In univariate analysis, hypoxia inducible factor 1 alpha,
Rho-GDP dissociation inhibitor α and citron/ rho-interacting serine-
threonine kinase 21 were signiﬁ  cant prognostic factors for disease-free
survival in the entire cohort of 130 NSCLC patients, but none were
signiﬁ  cant in multivariate analysis. 
The results demonstrate that the prognostic signiﬁ  cance of microarray
results can be partially validated using realtime RT-PCR, but secondary
validation using larger and independent series of tumours is necessary
to identify true prognostic marker genes.
P23
AN ASSESSMENT OF THE MODIFICATION OF DIET IN RENAL 
DISEASE (MDRD) EQUATION FOR ESTIMATING GFR IN
CANCER PATIENTS
E-L Bertram 1, LR Campbell 1, CG Fraser 2, P James 3,
HP Stevenson 2, EM Rankin 1, MS Highley 1
1 Department of Cancer Medicine, Ninewells Hospital, Dundee, United 
Kingdom, 2 Department of Biochemical Medicine, Ninewells Hospital, 
Dundee, United Kingdom, 3 Medicines Monitoring Unit, Ninewells
Hospital, Dundee, United Kingdom
51Cr-EDTA clearance  is the  gold standard assessment of GFR. However
this method  is not always available, and a 24 hour creatinine clearance
(CC) estimation  is often used. The MDRD equation might  be useful to
estimate GFR in ﬁ  elds other than renal medicine. We have compared CC
with the estimated GFR obtained from the MDRD1 equation and also the
Cockcroft and Gault2 (CG) and Wright3 (W) formulae, in a retrospective
analysis of cancer patients receiving MIC for NSCLC, or ECF for gastric
or oesophageal adenocarcinoma. These formulae require only serum and
demographic data.
Methods: 162 patients  (60  females and 102 males) were studied. 126
received MIC and 36 ECF. The median age of all patients was 62 years
(range 29-83). For both MIC and ECF, the median number of cycles received
was 4 (range 1-6). CC during these treatments was compared to estimates
of GFR obtained from MDRD, CG and W, derived from data obtained on
the same day as the CC. Creatinine was measured using a kinetic Jaffe
method; creatinine kinase measurements were unavailable. There were 105
observations with complete data for CG, and 292 for MDRD and W. A linear
regression model was ﬁ  tted for each of the three formulae. 
Results: W gave the closest estimates, accounting for 24% of total variance
(CG and MDRD accounted for 18% and 5% respectively). There were no
signiﬁ  cant differences according to whether MIC or ECF was used.
Conclusion: The MDRD equation, derived from a patient population with
renal impairment, is less predictive of CC in cancer patients than the W
formula, derived from a cancer patient population.
1 Levey AS, et al. (1999) Ann Intern Med 130: 461.
2 Cockcroft DW and Gault MH. (1976) Nephron 16: 31.
3 Wright JG, et al. (2001) Br J Cancer 84: 452.
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ARE WE PREVENTING THE PREVENTABLE – VENOUS
THROMBOEMBOLISM PROPHYLAXIS IN CANCER
R Jones, S Oliveros, R Deady, RCF Leonard 
Cancer Institute, Singleton Hospital, Swansea, United Kingdom
Venous Thromboembolism (VTE) is common in cancer patients and 
often a cause of death.  Post-mortem studies demonstrated rates of VTE
as high as 50% in cancer patients.  The risk of VTE complications in
malignancy is increased by surgery, chemotherapy (including adjuvant)
and hormone treatment.
In 2003 we undertook a retrospective audit of 69 consecutive patients
admitted to our cancer ward.  The purpose was to classify patients
according to their VTE risk as deﬁ  ned  by the Second Thrombosis
Risk Factors Consensus Group risk assessment model into moderate,
high and very high risk. [1] The main risk factors in our patients were
malignancy, immobility and presence of central venous catheters.  Using
the risk assessment model 6 of our patients were moderate risk, 37 high
risk and 26 patients very high risk.  All subsequent events during that
admission occurred in the very high risk group with 1 DVT, 1 PE and 2
sudden deaths.  None of these patients had received prophylaxis.  Only
8 patients (12%) were receiving any type of VTE prophylaxis and only
4 of these were in the very high risk group.
This study identiﬁ  ed the need to assess the VTE risk in all our patients
and to consider adopting a protocol for prophylaxis with LMWH in the
very high risk group and consider TEDS, as less interventional, for the
high risk group.  This point was emphasised by a recent study of 106
British oncologists, which showed that a quarter did not recognise the
thrombogenic effects of cancer treatments and that VTE prophylaxis is
not commonly used in patients undergoing treatment for cancer. [2]
1 THRIFT Consensus Group: 1998 Phlebology; 13: 87 – 89
2 Kirwan et al:  2003 BMJ; 327: 597 - 598
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PHYSICAL ACTIVITY IN CANCER CACHEXIA: DO WE KNOW
HOW ACTIVE OUR PATIENTS ARE?
M Dahele 1, L Wall 1, T Preston 2, K Fearon 1
1 United Kingdom, University of Edinburgh, Edinburgh, 2 United 
Kingdom, Scottish Universities Environmental Research Center,
East Kilbride
INTRODUCTION: 60-80% of patients with advanced upper gastrointestinal
(UGI) cancer are cachectic, increasing morbidity and mortality. Therapy should
improve function. It is unclear how active cachectic cancer patients are and
what determines their level of activity. It is not known how Performance Status
(PS) relates to objective activity, or how best to measure activity. Physical
activity is a novel integrative end-point providing objective patient data. This
study pilots the use of a commercial activity meter (activPAL professional,
PAL Technologies Ltd, Glasgow). The meter is worn mid-thigh and provides
detailed activity records including estimated energy expenditure (EEE).
AIMS: To determine if the activPAL meter is a practical tool for assessing
activity. To characterise activity in advanced cancer patients.
METHODS: UGI cancer patients with >5% weight loss have their WHO PS
recorded and then wear the activPAL meter for 1 week.
RESULTS:  Preliminary results from 5 patients. 1 additional patient excluded
due to technical failure. All 5 patients had severe cachexia.  
AGE SEX WL(%) WHO STEP(hrs) UP(%/
16hrs) 6s )
EPAL PPAL
55∗ M 39 2 7.3 18 18 1.1 1.5
59∗ M 19 2 14 36 1.21 .5
62 M 19 2 5.4 10 1.1 1.5
46∗ M 26 1 7.8 32 1.1 1.5
69 F 44 2 5.8 17 1.11 .5
∗ Receiving chemotherapy, WL Body Weight Loss, STEP Total hours spent
Stepping/wk, UP Extrapolated Percentage time spent Standing or Stepping/
16hr ‘day’, EPAL Estimated Physical Activity Level derived from EEE (MET),
PPAL Predicted PAL (MET)
SIGNIFICANCE: WHO PS does not reﬂ  ect patient activity. Stepping time,
time UP and EPAL demonstrate the extent of patient inactivity. The meter is
well tolerated. The study is ongoing. Additional work will assess activity in a
healthy group and validate the EEE function.
P26
AUDIT OF WEIGHT LOSS AND NUTRITIONAL SUPPORT
DURING RADICAL RADIOTHERAPY OF HEAD AND NECK 
MALIGNANCIES
SJ Brock, C Baughan, V Hall, J Noyce 
Wessex Radiotherapy Centre, Southampton, United Kingdom
Introduction. Patients with  head and neck malignancy are frequently
malnourished at presentation. nutritional status may be further compromised 
by treatment. the aim of this audit was to assess the weight loss of patients
undergoing radical radiotherapy and to introduce guidelines for weight loss
management.
Methods.  audit of weight loss in all patients receiving radiotherapy for 
head and neck malignancy from february to 0ctober 2001. initial and weekly
weights were recorded plus interventions (nil, dietician referral with no other 
intervention, dietician followed by ng or peg) during radiotherapy. guidelines
for weight loss management introduced with the aim of less than 10% of 
patients losing more than 5% of their initial weight. audit cycle completed 
between October 2002 and June 2003.
Results.  54 patients were identiﬁ  ed in the initial audit. the average weight
change as a percentage of initial weight was -3.8%(+1.2 to -13.3). 35% of 
patients lost more than 5% of their initial weight including 56% of patients
who saw the dietician without further intervention. on repeat of the audit, 60
patients were identiﬁ  ed. the average weight change as a percentage of initial
weight was -1.14% (+4.8 to  -8.2%). 6.6 % of patients (4 patients) lost more
than 5% of t heir  initial weight; all were chemoradiotherapy patients who
refused ng tube insertion. intervention rates and percentage weight change
according to intervention for the 2 audit spells are shown below. 
Conclusions. The introduction of guidelines resulted in earlier more effective
management of weight loss without increasing the number of interventions.
Intervention Rate 
2001
Rate
2003
Weight change
(% Of initial 
Weight) 2001
Weight change 
(% Of initial
Weight) 2003
Nil 50
%
48% -3.6
 (+3.9 to -10.3)
+0.5
(+2.6 to -1.8)
Dietician
only
30
%
37% -5.9
(+3.0 to -3.3)
-2.47
(+0.4 to -8.2)
NG / PEG 20
%
15
%
-6.3
(+1.5 to -13.3)
-1.7
(+3.4 to - 4.9)
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OPEN LABEL PHASE II STUDY INDUCTION CHEMOTHERAPY
USING CISPLATIN OR CARBOPLATIN AND VINORELBINE 
FOLLOWED BY CONCOMITANT CHEMO-IRRADIATION FOR 
UNRESECTABLE NON-METASTATIC NON-SMALL CELL LUNG 
CANCER
S H Bullard 1, G Thomas 2, S Hill 3, L Toy 5, M Collinson 4,
P Hajiannakis 1
1 Derriford Hospital, Plymouth, United Kingdom, 2 Leicester Royal
Inﬁ  rmary, Leicester, United Kingdom, 3 Pierre Fabre Onocology,
Winchester, United Kingdom, 4 Royal Cornwall Hospital, Truro, 
United Kingdom, 5 Royal Devon and Exeter Hospital, Exeter, United 
Kingdom
Introduction 
A multi-centre study to assess feasibility and tolerability of induction chemotherapy
followed by concomitant chemo-irradiation in the treatment of inoperable, but non-
metastatic non-small cell lung cancer (NSCLC).
Methods
A minimum of 40 patients (20 on each arm) will be treated under this protocol.
They will receive 4 cycles of e ither Cisplatin and V inorelbine or Carboplatin
and Vinorelbine (platinum agent is dependent on individual patient / physician).
Radiotherapy commences on day 1 of cycle 3, to a dose of 66Gy over 6.5 weeks.
During the radiotherapy, the chemotherapy agents are reduced by 20 – 40%. Toxicity
is assessed throughout the treatment, with treatment delays and dose reductions built
into the protocol.
Results
To date 24 patients have been entered into this study; 8 have been, or are being,
treated in the Carboplatin and Vinorelbine arm; the remaining 16 with Cisplatin and
Vinorelbine.  2 patients have been assessed as ineligible. 9 patients are currently
on treatment. In the 13 patients who have completed treatment to date, the best
response has been 2 CR, 8 PR, 3SD, 0 PD.  2 patients have proceeded to surgery
(one had pathCR).  As anticipated, chemotherapy and radiotherapy toxicities have
been recorded, but have been manageable. There was no severe pneumonitis. During
the post treatment period, to date, a median follow up of 10 (4-17) months has been
recorded.  During this time, three patients have progressed, one of who has since
died of PD.   Updated results will be presented at the meeting.
Conclusion
The results to date are encouraging and we continue with active recruitment.
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IDENTIFICATION OF A FAMILIAL PANCREATIC CANCER 
GENE BY FOCUSING HAPLOTYPE ANALYSIS USING LOH IN
SPORADIC CANCER
J Leslie 1, C McFaul 1, J Earl 1, B Azadeh 1, W Prime 1, D Bartsch 2,
T Harada 3, N Lemoine 3, R Sibson 4, J Neoptolemos 1, W Greenhalf 1
1 The University of Liverpool, Liverpool, United Kingdom,
2 Philipps-University, Marburg, Germany, 3 Hammersmith Hospital, 
London, United Kingdom, 4 Clatterbridge Cancer Research Trust, 
Bebington, United Kingdom
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly invasive cancer with poor 
prognosis accounting for 40,000 deaths per year in Europe. The genetic basis for 
the particularly aggressive nature of this cancer is not known. Our aim is to identify 
tumour suppressor genes that are inactivated in pancreatic cancer and so are targets 
for therapy and diagnosis. We are looking for a gene that is mutated in the germline 
of patients with a familial predisposition for pancreatic cancer (establishing the 
genes speciﬁ  city) and which is frequently mutated in sporadic pancreatic cancers. 
As a marker we are looking for regions of loss of heterozygosity (LOH).
The European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer 
(EUROPAC) has identiﬁ  ed over 80 families with an autosomal dominant genetic 
predisposition to pancreatic cancer (FPC). No gene has been identiﬁ  ed in these 
families, but by analogy with other cancer syndromes it is most likely to be a tumour 
suppressor and is likely to be affected by somatic mutations in sporadic cases of 
pancreatic cancer. So we expect to see loss of the non-mutated allele in the sporadic
cases (LOH).
EUROPAC in collaboration with the German Familial Pancreatic Cancer registry 
(FaPaCa) will carry out haplotyping to identify chromosomal regions associated
with the disease. One such region has already been identiﬁ  ed as the 4q32-34 region, 
which is associated with pancreatic cancer in a single, large American family. We 
have carried out haplotype analysis of this region and identiﬁ  ed 7 families where the 
disease gene cannot be associated with 4q32-34.  By identifying regions of LOH in 
sporadic cases we will determine the next region to be haplotyped.
One hundred and eleven H&E stained slides from archived parafﬁ  n-embedded tissue 
blocks were pathologically assessed for PDAC. Sections of 7-10 micron in thickness 
were cut from each block and needle or laser capture microdissected to isolate the
cancerous tissue from the non- cancerous areas. DNA was extracted and quantiﬁ  ed 
using Real Time PCR Light Cycler™ (Roche) and UV spectrophotometry.
Comparative hybridisation using whole genome BAC microarrays from the Sanger 
centre is being used to identify possible regions with LOH.
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P53 MUTATIONS IN PATIENTS WITH PANCREATIC CANCER 
AND CHRONIC PANCREATITIS
L Yan 1, C McFaul 1, N Malats 2, J Threadgold 1, N Howes 1, J Leslie 1, 
T Wong 1, M Lombard 1, H Smart 1, I Gilmore 1, J Evans 1, P Real 2,
J Neoptolemos 1, W Greenhalf 1
1 The University of Liverpool, Liverpool, United Kingdom, 2 IMIM, 
Barcelona, Spain
We  have developed a technique for detection of p53 mutations in pancreatic
juice. with.  We aim to show that p53 mutations in pancreatic juice correspond
to p53 mutations in tumour tissue and that these are speciﬁ  c for cancer. We also
compared p53 mutation status with the mutation status of K-Ras and methylation
of the promoter of the tumour suppressor p16.
Mutant p53 was identiﬁ  ed in the juice of 23 (45%) of 51 patients with pancreatic
ductal adenocarcinoma (PDAC). 2 (4%) of 49 chronic pancreatitis patients. 51
patients had billiary tract stones none of these patients had p53 mutations. There
was no correlation in PDAC between p53 and K-Ras mutations (p=0.25, N=48
Fisher’s exact). Matched tissue was available in 23 PDAC cases. In 9 (70%) of
13 cases with p53 mutations in tissue mutations were found in pancreatic juice,
in 2 out of 10 cases with no p53 mutation in tissue a p53 mutation was identiﬁ  ed
in juice. The two chronic pancreatitis patients with p53 mutations were aged 19
and 43 when the samples were taken. The 43 year old patient has since died,
this patient also had mutant Ras. The 19-year-old patient has now been followed
up for 5 years with no sign of malignancy. This patient had wild type K-Ras in
pancreatic juice and no methylation of the p16 promoter. A tissue sample from
this patient was tested for p53 mutation and none was identiﬁ  ed. Age of onset of
PDAC is lower for patients with a p53 mutation than for patients with wild type
p53 (this is signiﬁ  cant for the subgroup of patients over 70 years of age, logrank
p=0.014, N=10 mutant and 9 wild type). Combining both p53 and K-Ras for
the over 70 age group indicates a later age of onset with patients with both wild
type K-Ras and wild type p53 (p=0.017, N= 7 both mutant, 5 both wild type).
For survival after diagnosis there seems little difference between p53 wild type
and mutant patients.
CONCLUSION: p53 can be detected in pancreatic juice and this corresponds
to p53 in tumour of PDAC patients. However, it can also be detected in patients
with chronic pancreatitis although less frequently. p53 mutations seem to be
associated with patients who develop PDAC soon after the age of 70 but earlier
age of onset before this does not seem to be associated with p53.
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